We are dedicated to bringing innovative medicines to patients with neurodegenerative disorders that can arrest or reverse their disease progression. As part of our strategy, we look for collaborations with partners to create dendrimer enabled therapies targeting various pathways of microglial biology.

We look for partnering opportunities with therapeutic assets that need to achieve the following product profile:

  1. Delivery across the blood brain barrier
  2. Selectively target 'activated' microglia
  3. Eliminate or reduce off target toxicity and improve drug clearance
  4. Require flexible delivery and dosage formats

We welcome the opportunity to learn more about how we can work together. To further explore partnering opportunities with Orpheris, please contact:

Matt Brewer
Acting Chief Business Officer

Contact Us: